ANESTAGEL™

A NEW, OPIOID-FREE PAINKILLER

  • Non-opioid painkiller – pre-clinical stage
  • Lasts up to 300% longer than leading competitor*
  • 22 U.S. Patents

 

InSitu Biologics is currently in the pre-clinical stage

InSitu Biologics is currently raising capital to fund clinical trials.

Having filled the Tier 3 share allotment we are now only accepting reservations. We have filed with the SEC to request Qualification of a new share price. Click the link below to make your reservation and lock in the new price when it is available.

Learn More About Investing

Who We Are

InSitu Biologics is an emerging biotech company focusing on development of AnestaGel™, a long-lasting and long-acting non-opiate painkiller. The sustained release drug AnestaGel is expected to be used in post-operative surgical procedures. AnestaGel may be a solution in relieving pain for broken bones, cosmetic surgery, hip/knee replacements, hernia, and more.

Latest News & Updates

Pre-Clinical Results

As compared to EXPAREL (Pacira, Inc.), the industry leading post-operative pain treatment.

300% Longer

Initial animal study revealed AnestaGel™ lasted up to 300% longer

8x More Capacity

AnestaGel™ carried 8 times more payload

72+ Hours

AnestaGel™ had full nerve block beyond 72 hours

See our study at the Journal of Pain Research

Timeline

  • 2016

    Q1
    Filed additional patent(s)

    Q2
    White Paper published

    Q3
    Completed maximum dosing study with no toxicity

    Q4
    Presented at PODD-Boston

  • 2017

    Q1
    Completed first GLP study

    Q2
    Proved more pain relief compared to Exparel in pre-clinical study

    Q3
    GLP publication accepted

    Q4
    Raised over $400k

  • 2018

    Q1
    Completed Financial Audit
    Converted all debt
    Filed $10,000,000 RegA+ Offering

    Q2
    Launch RegA+ Offering
    Announce GLP Paper by Hutchins & Taylor

    Q3
    Begin Phase 1 program manufacturing

    Q4
    Announce final GLP Study results

  • 2019

    Q1
    Expect approval for Phase 1 Clinical Study of AnestaGel

    Q2
    Clinical Trials

    Q3
    Clinical Trials

    Q4
    TBD

The Executive Team

Meet the InSitu Biologics Executive Team

James Segermark

CEO

Jim has been the founder, inventor, investor, and owner operator in many med-tech ventures. Jim began working on the Matrix technology in 2007 and co-founded InSitu Biologics in 2014. Jim is an inventor on over 40 issued patents for medical products, and specializes in the total enterprise of bringing proprietary products from “just an idea” through design, scaled up manufacturing, and “to the patient”. Jim earned his Bachelor of Science from Carroll University in Waukesha, Wisconsin and his MBA from Cardinal Stritch University in Milwaukee.

Bill Taylor

Chief Scientist

Bill is a Co-Founder of InSitu Biologics, beginning his work on the Matrix in 2007. Bill is a successful medical product development programs manager and scientist, and has been awarded over $900k in government research grants, and authored industry papers in chemical remediation and demilitarization utilizing biological systems. Bill has his Bachelor of Science from the University of Minnesota with a double major in Chemical Engineering and Biology.